By K. John Morrow Jr., Ph.D.
Published with permission from Genetic Engineering & Biotechnology News (GEN)
Bioprocessing 4.0 (or Biopharma 4.0) is becoming more tangible every day; according to Darren Verlenden, head of bioprocessing at MilliporeSigma. He adds that the company has multiple initiatives and programs that are defining the application of Industry 4.0 principles for our products, technologies, and services. “The industry is at a convergence of digital and process technologies that offers significant value beyond incremental improvement within individual silos,” he said.
Verlenden described the digital environment as consisting of advanced automation platforms, interconnected bioprocessing systems, operators, and facilities, advanced data and process analytics, and finally, building bridges between end users, manufacturing sites, and suppliers.